MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xinn.2026.101305

Медицинская библиотека · Innovation (Cambridge (Mass.)) · 2026

Chinese consensus on first-line precision therapy for advanced gastric cancer.

Zhang Xiaotian, Sheng Weiqi, Xie Tong, Peng Zhi, Liang Han, Li Enxiao, Wang Fenghua, Zhang Jun, Liu Tianshu, Zhu Xiaodong, Cai Muyan, Wu Yinying, Deng Ting, Gou Hongfeng, Sun Yongkun, Wei Jia, He Yifu, Huang Dan, Ying Jie'er, Bai Wei, Jin Xuan, Kang Weiming, Li Ning, Li Zhiwei, Liu Jing, Lu Yuanyuan, Qiu Hong, Qiu Miaozhen, Qu Xiujuan, Song Yan, Sun Yan, Sun Yu, Wang Jian, Wang Yakun, Xu Huiting, Yin Fei, Zhao Liying, Liu Yunpeng, Shen Lin, Chinese Clinical Society Gastric Cancer Committee, China Anti-Cancer Association Cancer Informatics Management Committee, China Anti-Cancer Association Cancer Pathology Specialized Committee, China Anti-Cancer Association Committee of Cancer Precision Therapy

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Gastric cancer (GC) remains a formidable public health challenge in China, characterized by a high incidence and mortality rate. A significant proportion of patients are diagnosed with advanced or metastatic disease, where traditional chemotherapy has historically offered limited survival benefits. However, driven by a deeper molecular understanding of GC heterogeneity, the paradigm of GC treatment is undergoing a revolutionary shift from a "one size fits all" approach toward precision medicine. The identification of predictive biomarkers, such as human epidermal growth factor receptor 2 (HER2/ERBB2; MIM: 164870) expression, microsatellite instability-high (MSI-H) status, PD-L1 (CD274; MIM: 605402) expression, and Claudin 18.2 (CLDN18; MIM: 609210) overexpression, has established biomarker-guided strategies as the unequivocal future direction for managing advanced GC. In particular, the emergence of immune checkpoint inhibitors (ICIs) and agents targeting Claudin 18.2 has revolutionized the landscape of first-line (1L) treatment for GC. China has achieved accelerated breakthroughs in gastric cancer drug research and development, leading to more innovative therapies and improved diagnostic/treatment regimens, providing patients with more abundant and effective treatment options and significantly improving the landscape of diagnosis and treatment. Nevertheless, integrating complex biomarkers and novel agents into practice poses challenges, including inconsistencies in biomarker testing and the need for nuanced treatment regimen selection. Without standardized guidelines, inconsistent application may lead to suboptimal patient outcomes and inefficient use of healthcare resources. This expert consensus has been jointly formulated with the aim of further enhancing and standardizing the biomarker testing and precision medicine of 1L therapy for advanced GC.

Для цитирования: Zhang Xiaotian, Sheng Weiqi, Xie Tong, Peng Zhi, Liang Han, Li Enxiao, Wang Fenghua, Zhang Jun, Liu Tianshu, Zhu Xiaodong, Cai Muyan, Wu Yinying, Deng Ting, Gou Hongfeng, Sun Yongkun, Wei Jia, He Yifu, Huang Dan, Ying Jie'er, Bai Wei, Jin Xuan, Kang Weiming, Li Ning, Li Zhiwei, Liu Jing, Lu Yuanyuan, Qiu Hong, Qiu Miaozhen, Qu Xiujuan, Song Yan, Sun Yan, Sun Yu, Wang Jian, Wang Yakun, Xu Huiting, Yin Fei, Zhao Liying, Liu Yunpeng, Shen Lin, Chinese Clinical Society Gastric Cancer Committee, China Anti-Cancer Association Cancer Informatics Management Committee, China Anti-Cancer Association Cancer Pathology Specialized Committee, China Anti-Cancer Association Committee of Cancer Precision Therapy. Chinese consensus on first-line precision therapy for advanced gastric cancer.. Innovation (Cambridge (Mass.)). 2026. DOI: 10.1016/j.xinn.2026.101305.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.